Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate and Severe Nasolabial Folds
Launched by GALDERMA R&D · Apr 28, 2015
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chinese origin
- • Subjects intent to undergo correction of both NLFs with a Wrinkle Severity Rating Scale (WSRS) of 3 on both side or 4 on both side.
- • Subjects willing to abstain from other facial plastic surgical or cosmetic procedures during the study period.
- • Singed Informed Consent
- Exclusion Criteria:
- • Subjects with traumatic scars or ongoing active skin disease in the area to be treated
- • Permanent inplant or filler, including fat injection placed in the area to be treated
- • Previous tissue augmentation therapy in the NLFs with non-permanent filler within 12 months prior to inclusion
- • Any medical condition in the opinion of the treating investigator who will make the subject unsuitable for inclusion
About Galderma R&D
Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Wuhan, , China
Zhejiang, , China
Patients applied
Trial Officials
Q-Med AB
Study Director
Galderma R&D
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials